Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2018-12-11

FDA Approved: IMODIUM MULTI-SYMPTOM RELIEF — Supplemental Application (Kenvue Brands LLC)

View source ↗

Summary

The FDA approved a supplemental application for Imodium Multi-Symptom Relief (loperamide hydrochloride and dimethicone) submitted by Kenvue Brands LLC, indicati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IMODIUM MULTI-SYMPTOM RELIEF (LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE)

Snippet

SUPPL AP for IMODIUM MULTI-SYMPTOM RELIEF (LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE)